New drug aims to supercharge immune system against prostate cancer

NCT ID NCT05361798

Recruiting now Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 12, 2026 · Updated 6 times

Summary

This phase II trial tests whether adding an experimental drug called PDS01ADC to standard radiation and hormone therapy can help the immune system fight prostate cancer. About 65 men with high- or intermediate-risk prostate cancer that hasn't spread will take part. Some will get the drug after radiation, while others will receive only standard care, and researchers will compare immune responses.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PDS01ADC (an immunocytokine drug given as a shot under the skin)
What this could lead to: If it works, this could lead to a new combination treatment that helps the immune system better fight prostate cancer and reduces the chance of the cancer coming back.
What could go wrong: This is an early phase II trial with only 65 people, so results may not apply to everyone. The drug may cause side effects or fail to improve outcomes compared to standard therapy alone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER OF PROSTATE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANCER OF PROSTATE

Contacts and locations

Locations

National Institutes of Health Clinical Center
RECRUITING

Bethesda, Maryland, 20892, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.